These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15117993)

  • 1. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
    Leu KM; Ostruszka LJ; Shewach D; Zalupski M; Sondak V; Biermann JS; Lee JS; Couwlier C; Palazzolo K; Baker LH
    J Clin Oncol; 2004 May; 22(9):1706-12. PubMed ID: 15117993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
    Hensley ML
    Curr Opin Oncol; 2010 Jul; 22(4):356-61. PubMed ID: 20520541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
    Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
    Oncologist; 2012; 17(3):321. PubMed ID: 22363068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
    Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
    Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
    Lee EM; Rha SY; Lee J; Park KH; Ahn JH
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
    Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
    PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
    Bay JO; Ray-Coquard I; Fayette J; Leyvraz S; Cherix S; Piperno-Neumann S; Chevreau C; Isambert N; Brain E; Emile G; Le Cesne A; Cioffi A; Kwiatkowski F; Coindre JM; Bui NB; Peyrade F; Penel N; Blay JY;
    Int J Cancer; 2006 Aug; 119(3):706-11. PubMed ID: 16496406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
    Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
    BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
    Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
    Verschraegen CF; Arias-Pulido H; Lee SJ; Movva S; Cerilli LA; Eberhardt S; Schmit B; Quinn R; Muller CY; Rabinowitz I; Purdy M; Snyder D; Bocklage T
    Ann Oncol; 2012 Mar; 23(3):785-790. PubMed ID: 21746804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].
    Bay JO; Cabrespine A; Gilliot O; Bailly C; Vincent C; Mishellany F; Gimbergues P
    Bull Cancer; 2007; 94 Spec No Actualites():S122-6. PubMed ID: 17845981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.
    Maki RG
    Oncologist; 2007 Aug; 12(8):999-1006. PubMed ID: 17766660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
    Munhoz RR; D'Angelo SP; Gounder MM; Keohan ML; Chi P; Carvajal RD; Singer S; Crago AM; Landa J; Healey JH; Qin LX; Hameed M; Ezeoke MO; Singh AS; Agulnik M; Chmielowski B; Luke JJ; Van Tine BA; Schwartz GK; Tap WD; Dickson MA
    Oncologist; 2015 Nov; 20(11):1245-6. PubMed ID: 26449382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials.
    Ducoulombier A; Cousin S; Kotecki N; Penel N
    Crit Rev Oncol Hematol; 2016 Feb; 98():73-80. PubMed ID: 26555460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
    Maki RG; Wathen JK; Patel SR; Priebat DA; Okuno SH; Samuels B; Fanucchi M; Harmon DC; Schuetze SM; Reinke D; Thall PF; Benjamin RS; Baker LH; Hensley ML
    J Clin Oncol; 2007 Jul; 25(19):2755-63. PubMed ID: 17602081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
    Mora J; Cruz CO; Parareda A; de Torres C
    J Pediatr Hematol Oncol; 2009 Oct; 31(10):723-9. PubMed ID: 19727011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
    Navid F; Willert JR; McCarville MB; Furman W; Watkins A; Roberts W; Daw NC
    Cancer; 2008 Jul; 113(2):419-25. PubMed ID: 18484657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
    Ebeling P; Eisele L; Schuett P; Bauer S; Schuette J; Moritz T; Seeber S; Flasshove M
    Onkologie; 2008 Feb; 31(1-2):11-6. PubMed ID: 18268394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.